Tripathy, D., Dolezal, M. V., Abramson, V. G., Chittoria, N., Ehsani, S., Pestell, R. G., Rugo, H. S., Rui, H., Adams, D. L., Meidling, J., Lataillade, M., Lalezari, J. P. (2026). Safety and 5-year survival following treatment with leronlimab plus physician’s choice combination therapy in patients with metastatic triple-negative breast cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e13109